Cytokine News and Research

RSS

Prior MMR or Tdap vaccination may reduce risk of severe COVID-19

Researchers in the United States have shown that prior Measles-Mumps-Rubella (MMR) or Tetanus-Diphtheria-pertussis (Tdap) vaccination may reduce the risk of severe outcomes in patients with coronavirus disease 2019 (COVID-19).

5 May 2021

Nanoparticle (SpFN) vaccine candidate elicits multifactorial cellular immune responses against SARS-CoV-2 in vivo

Researchers have developed a promising new anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)vaccine candidate that utilizes nanotechnology and shows robust, long-lived immunity in mouse models.

5 May 2021

Stem cell therapy for COVID-19 and ARDS

In a review paper recently uploaded to the journal Biomedicine & Pharmacotherapy by Mahendiratta et al. (May 2021) the applicability of stem cells in treating severe SARS-CoV-2 infection is investigated, with regard to ARDS therapy.

5 May 2021

Evidence that elevated blood glucose is a significant risk factor for severe COVID-19

The literature analysis pointed to elevated blood glucose levels as a leading facilitator in the progression of COVID-19. Evidence linking elevated glucose to various steps in the life cycle of the virus and presentation of COVID-19 symptoms were also found.

3 May 2021

SARS-CoV-2 study in human gut organoids

Most of the major life-threatening symptoms of COVID-19 disease are associated with the host's generation of an exacerbated pro-inflammatory immune response. Many studies have correlated the intensity of the immune response with the severity of disease.

3 May 2021

UTHSC professor receives $2.87 million to study genetic alterations associated with Gulf War illness

The National Institute of Environmental Health Sciences has awarded Byron C. Jones, PhD, professor in the Department of Genetics, Genomics, and Informatics at the University of Tennessee Health Science Center, $2.87 million for his continuing study of genetic alterations associated with Gulf War illness among former military personnel.

30 Apr 2021

New study reveals mechanisms that result in lethal COVID-19

A new study is drawing the most detailed picture yet of SARS-CoV-2 infection in the lung, revealing mechanisms that result in lethal COVID-19, and may explain long-term complications and show how COVID-19 differs from other infectious diseases.

30 Apr 2021

Researchers discover how SARS-CoV-2 hijacks human cell machinery to blunt immune response

Researchers at University of California San Diego School of Medicine have discovered one way in which SARS-CoV-2, the coronavirus that causes COVID-19, hijacks human cell machinery to blunt the immune response, allowing it to establish infection, replicate and cause disease.

29 Apr 2021

Study reveals the role of lncRNAs in immune dysfunction during severe COVID-19

Scientific studies rarely focus on long non-coding RNA molecules (lncRNAs), even though they potentially regulate several diseases. The role of several lncRNAs in anti-viral inflammatory response regulation has recently been reported.

28 Apr 2021

Celastrol shows potential anti-SARS-CoV-2 activity

A new study published on the bioRxiv* preprint server focuses on the in-silico predictions to repurpose existing drug compounds, that may have the ability to reverse the SARS-CoV-2 gene expression induced in host cells.

23 Apr 2021

Researchers discover molecule that provides dual protection against vascular inflammation

A multidisciplinary team of researchers from Duke-NUS Medical School and the Agency for Science, Technology and Research (A*STAR) in Singapore discovered a new mitochondrial peptide called MOCCI that plays an important role in regulating inflammation of blood vessel and immunity.

22 Apr 2021

Researchers aim to better understand clinical features associated with COVID-19 mortality

To better understand the COVID-19 clinical feaures associated with mortality, an interdisciplinary team of researchers has investigated important factors and their influence on a patient’s death.

22 Apr 2021

Research offers new insights on the significance of hyperinflammation following SARS-COV-2 infection

Severe cases of COVID-19 can involve extensive inflammation in the body, and clinicians have wondered if this state is similar to what are called cytokine storm syndromes, in which the immune system produces too many inflammatory signals that can sometimes lead to organ failure and death.

21 Apr 2021

SARS-CoV-2-associated ssRNAs trigger inflammation and immunity via toll-like receptors

Severe COVID-19 causes sepsis-like manifestations, intense lung injury, and multi-organ failure, all associated with the overproduction of pro-inflammatory cytokines. This "cytokine storm" directly correlates with poor prognosis in this subgroup of patients.

21 Apr 2021

Can an immunosuppressive cancer drug promote SARS-CoV-2 entry into host cells?

A new study shows that rapamycin, an immunosuppressive drug used in some cancers, and its analogs, may have an undesirable effect on viral entry into the host cells. This finding could inform their use to treat symptomatic COVID-19.

20 Apr 2021

Research team identifies new factor in the development of psoriasis

Psoriasis is a common inflammatory skin condition. The underlying genetic factors have not yet been sufficiently researched.

19 Apr 2021

Bristol-based new biotech company is developing ground-breaking treatments for Covid-19

A team of top scientists from the University of Bristol have announced the formation of a new biotech company that is developing ground-breaking and newly patented potential treatments for Coronavirus.

16 Apr 2021

Can biomaterials offer novel therapeutic strategies against COVID-19?

A team of scientists reviews the current and potential impact of the biomaterial sciences on the COVID-19 pandemic.

15 Apr 2021

High antibody and inflammatory mediator levels may predict severe COVID-19

A new study reports on biomarkers could help predict the progression of the viral illness to dangerous levels early enough to enable timely intervention.

15 Apr 2021

Ponatinib identified as a potent inhibitor of SARS-CoV2-induced cytokine storm

Researchers at the Human Biology Division, Fred Hutchinson Cancer Research Center in Washington, United States, found that the FDA-approved, multi-kinase inhibitor Ponatinib is a potent inhibitor of the N-terminal domain (NTD) -mediated cytokine storm. Ponatinib is an oral drug used for the treatment of chronic myeloid leukemia (CML).

14 Apr 2021

Cytokine News and Research

Prior MMR or Tdap vaccination may reduce risk of severe COVID-19

Nanoparticle (SpFN) vaccine candidate elicits multifactorial cellular immune responses against SARS-CoV-2 in vivo

Stem cell therapy for COVID-19 and ARDS

Evidence that elevated blood glucose is a significant risk factor for severe COVID-19

SARS-CoV-2 study in human gut organoids

UTHSC professor receives $2.87 million to study genetic alterations associated with Gulf War illness

New study reveals mechanisms that result in lethal COVID-19

Researchers discover how SARS-CoV-2 hijacks human cell machinery to blunt immune response

Study reveals the role of lncRNAs in immune dysfunction during severe COVID-19

Celastrol shows potential anti-SARS-CoV-2 activity

Researchers discover molecule that provides dual protection against vascular inflammation

Researchers aim to better understand clinical features associated with COVID-19 mortality

Research offers new insights on the significance of hyperinflammation following SARS-COV-2 infection

SARS-CoV-2-associated ssRNAs trigger inflammation and immunity via toll-like receptors

Can an immunosuppressive cancer drug promote SARS-CoV-2 entry into host cells?

Research team identifies new factor in the development of psoriasis

Bristol-based new biotech company is developing ground-breaking treatments for Covid-19

Can biomaterials offer novel therapeutic strategies against COVID-19?

High antibody and inflammatory mediator levels may predict severe COVID-19

Ponatinib identified as a potent inhibitor of SARS-CoV2-induced cytokine storm

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News